BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05686239 (Inidascamine in Cognitive Impairment Associated With Schizophrenia): BVCT ex-ante prediction vs. reported outcome

On 24 Apr 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 25 Jul 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05686239
Drug Name
Inidascamine
Drug MoA
Inidascamine (RL-007)
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Cognitive Impairment Associated With Schizophrenia
Human Patients
242
Sponsor
ATAI Life Sciences
Phase
Phase 2

Prediction of , index 1990

Prospective Prediction
Prediction Index
1990
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in MCCB inferior to KarXT)
Technical Prediction
FAILURE (statistically maybe significant yet very weak additive clinical benefit in MCCB compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
92 days in advance
Readout Data Interpretation
inidascamine failed to achieve the primary endpoint in MCCB score at week 6
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase
Phase 2
Status
Completed
Enrollment
242
Lead sponsor
Recognify Life Sciences
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS); Cognitive Impairment; Schizophrenia
Interventions
DRUG: RL-007 (Inidascamine); DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-12-08
Primary completion
2025-04-09
Completion
2025-04-09
Primary outcomes
  • MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite (6 weeks)

NCT05686239 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials